8925174 Raw data Biomed Research Inte.rar

Name: 8925174 Raw data Biomed Research Inte.rar
Creator: Chengfang Shangguan
Published: 2018-05-31T00:00:00+08:00

Figshare2018-05-31 更新2026-04-08 收录

甲状腺癌靶向治疗

放射碘疗效增强

数据链接：

https://figshare.com/articles/8925174_Raw_data_Biomed_Research_Inte_rar/6396254/1 数据链接链接失效反馈

官方服务：

资源简介：

miR-504 antagomir up-regulates NIS expression and improves the effect of 131 I therapy in thyroid cancer

提供机构：

Chengfang Shangguan

创建时间：

2018-05-31

Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancer. Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancer

甲状腺癌靶向治疗

ERK信号通路

Our findings establish that BRAF- and RAS-mutant thyroid cells respond differentially to DEL-22379, which cannot be explained by the previously described mechanism of action of the inhibitor. Nonethel

NIAID Data Ecosystem40

DataSheet_1_The ETS Inhibitor YK-4-279 Suppresses Thyroid Cancer Progression Independent of TERT Promoter Mutations.pdf

甲状腺癌靶向治疗

TERT基因调控

Hotspot mutations in the core promoter region of the telomerase reverse transcriptase (TERT) gene have been well established to associate with aggressive clinical characteristics, radioiodine refracto

NIAID Data Ecosystem20

DataSheet1_In Silico Screening and Validation of PDGFRA Inhibitors Enhancing Radioiodine Sensitivity in Thyroid Cancer.DOCX

甲状腺癌靶向治疗

药物虚拟筛选

Aberrant activation of platelet-derived growth factor receptor α (PDGFRA) has been implicated in tumorigenesis and radioiodine resistance of thyroid cancer, indicating its therapeutic potential. In th

NIAID Data Ecosystem10

Effects of siRNA on RET/PTC3 Junction Oncogene in Papillary Thyroid Carcinoma: From Molecular and Cellular Studies to Preclinical Investigations

甲状腺癌靶向治疗

siRNA药物研发

RET/PTC3 junction oncogene is typical of radiation-induced childhood papillary thyroid carcinoma (PTC) with a short latency period. Since, RET/PTC3 is only present in the tumour cells, thus represents

NIAID Data Ecosystem20

Loss of tumor cell MHC Class II drives MAPK-inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers

化疗耐药机制

甲状腺癌靶向治疗

Cancer cells present neoantigens dominantly through MHC class I (MHCI) to drive tumor rejection through cytotoxic CD8+ T-cells. There is growing recognition that a subset of tumors express MHC class I

NIAID Data Ecosystem10

8925174 Raw data Biomed Research Inte.rar

资源简介：

相关数据集